Saturday 17 October 2026
Export TELA’s income statement to Excel — free account
TELA Bio, Inc.
TELA Healthcare Medical Devices
TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 4.49%, EPS grew 9.09%, free cash flow fell 17.7% and total debt rose 35.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
0.98
0.03
−2.97%
Follow TELA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 3 | 3 |
+8 more TTM periods Free account |
| 1,232.54% | (616.62%) | (223.35%) | 1,654.21% | ||
| (64.71%) | (54.15%) | (46.23%) | (68.06%) | ||
ROIC |
(217.11%) | (189.96%) | (189.70%) | (166.17%) | |
Return on Tangible Assets |
(107.46%) | (81.93%) | (64.90%) | (94.46%) | |
Average Days of Receivables |
44.02 | 43.88 | 47.05 | 53.40 | |
Free Cash Flow per Share |
(0.55) | (0.53) | (0.61) | (0.69) | |
Free Cash Flow |
(31.62) | (30.20) | (28.67) | (31.50) | |
Capital Expenditures |
(0.48) | (0.53) | (0.45) | (0.62) | |
| Other line items | |||||
Cash ROIC |
(44.76%) | (33.48%) | (25.41%) | (43.29%) | |
Accounts Receivable Turnover |
7.66 | 7.97 | 7.85 | 6.85 | |
Accounts Payable Turnover |
10.96 | 6.61 | 11.47 | 10.25 | |
Inventory Turnover |
2.26 | 2.03 | 2.15 | 1.98 | |
Average Days of Payables |
41.53 | 54.49 | 32.98 | 34.83 | |
Days of Inventory on Hand |
159.29 | 170.89 | 157.35 | 169.64 | |
Tax Rate |
0.01 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.94% | 11.17% | 11.49% | 11.84% | |
Selling, General and Administrative Expense of Revenue |
98.43% | 97.92% | 98.26% | 101.42% | |
Share Based Compensation of Revenue |
4.00% | 4.42% | 4.73% | 5.29% | |
Interest Coverage |
(4.88) | (5.56) | (6.44) | (7.25) | |
Operating CF/Net income |
0.76 | 0.74 | 0.73 | 0.79 | |
Depreciation/Fixed assets |
0.49 | 0.47 | 0.45 | 0.47 | |
Capex/Depreciation |
(0.48) | (0.53) | (0.44) | (0.59) | |
Revenue per Share |
1.39 | 1.41 | 1.71 | 1.70 | |
Operating CF per Share |
(0.54) | (0.52) | (0.60) | (0.68) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates